Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Elutia Inc ELUT

Healthcare Biotechnology
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use... see more

Recent & Breaking News (NDAQ:ELUT)

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro(TM) Testing Method

GlobeNewswire May 28, 2025

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro(TM) Sales

GlobeNewswire May 8, 2025

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

GlobeNewswire May 1, 2025

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

GlobeNewswire May 1, 2025

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

GlobeNewswire April 22, 2025

Elutia Initiates EluPro(TM) Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

GlobeNewswire April 21, 2025

Elutia Confirms No Material Impact from Global Tariffs

GlobeNewswire April 14, 2025

EluPro(TM) Named as 2025 Edison Award Winner

GlobeNewswire April 4, 2025

Elutia to Participate in Upcoming Investor Conferences

GlobeNewswire April 3, 2025

Elutia to Debut EluPro(TM) at HRS 2025 - Experience the Difference Biology Makes

GlobeNewswire April 2, 2025

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro(TM)

GlobeNewswire March 27, 2025

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

GlobeNewswire March 25, 2025

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro(TM) in Pilot Launch Sets the Stage for Full Commercial Roll-Out

GlobeNewswire March 6, 2025

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

GlobeNewswire February 20, 2025

Elutia Announces $15.0 Million Registered Direct Offering

GlobeNewswire February 3, 2025

Elutia Announces Full Launch of EluPro(TM) Following Strong Initial Demand

GlobeNewswire January 14, 2025

Elutia Announces EluPro(TM) GPO Agreement with Southern Strategic Sourcing Partners

GlobeNewswire January 6, 2025

Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

GlobeNewswire December 2, 2024

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

GlobeNewswire November 14, 2024

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

GlobeNewswire November 13, 2024